Related Experiment Video
Updated: Jul 11, 2026

Using Visual and Narrative Methods to Achieve Fair Process in Clinical Care
Published on: February 16, 2011
A Tale of Two Surges: Differences in Outcomes in the COVID-19 Pandemic in a Community Teaching Hospital in
Gabriela C Milla-Godoy1, Klaorat Prasongdee1, Cagney Cristancho1
1Internal Medicine, MetroWest Medical Center, Tufts University School of Medicine, Framingham, USA.
Insights
COVID-19 outcomes improved in the second surge due to new treatments like remdesivir and dexamethasone. Patients in the first surge had more comorbidities and worse survival predictions, impacting outcomes.
Area of Science:
- Infectious Diseases
- Epidemiology
- Critical Care Medicine
Background:
- The COVID-19 pandemic necessitated rapid therapeutic implementation.
- This study compares patient characteristics and outcomes between two distinct COVID-19 surges (March 2020 and December 2020) at MetroWest Medical Center.
- Understanding these differences is crucial for optimizing patient care during public health crises.
Purpose of the Study:
- To contrast demographic, clinical, and comorbidity profiles of COVID-19 patients during two surges.
- To compare treatment strategies, including remdesivir and dexamethasone administration.
- To evaluate and compare primary endpoints: intensive care unit (ICU) admission, mechanical ventilation, and mortality rates.
Main Methods:
- Retrospective data extraction from 419 inpatients with confirmed SARS-CoV-2 infection (PCR positive).
- Data collected included demographics, comorbidities (Charlson Comorbidity Index - CCI), treatments, and outcomes.
- Patients were divided into two cohorts based on admission surge: March-June 2020 (S1) and November-December 2020 (S2).
Main Results:
- The first surge (S1) included more patients from nursing homes (47%) and those with dementia (33%), with a higher median CCI and poorer predicted survival (21% vs 53%).
- Treatment patterns shifted significantly: remdesivir use increased from 5% in S1 to 60% in S2, and dexamethasone was introduced in S2 (69%).
- ICU admission (27% vs 14%), mechanical ventilation (11% vs 11%), and overall mortality (25% vs 9%) were significantly lower in the second surge (S2).
Conclusions:
- COVID-19 patients admitted during the second Massachusetts surge showed significantly improved clinical outcomes, especially reduced mortality, compared to the early pandemic.
- The introduction and increased use of dexamethasone and remdesivir likely contributed to better outcomes.
- Differences in patient populations (more vulnerable patients in S1) and baseline health status also influenced the observed outcome disparities.
Abstract:
Background The coronavirus disease 2019 (COVID-19) pandemic has challenged the scientific community in the prompt implementation of therapies. We report and contrast characteristics and outcomes from two COVID-19 surges in March 2020 and December 2020 in patients at MetroWest Medical Center in Framingham. Methods The study was conducted at MetroWest Medical Center. We extracted the data of 315 patients from March 17, 2020, to June 30, 2020, and 104 patients from November 19, 2020, to December 30, 2020. All patients were inpatients and had confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by polymerase chain reaction (PCR). We extracted the patient's demographic information, clinical data, and given treatments. We also examined comorbidities and categorized them by the Charlson Comorbidity Index (CCI). The primary endpoints were intensive care unit (ICU) level of care, mechanical ventilation, or death. Results A total of 419 patients were studied. The median age was 76. During the first surge (S1), 150 (47%) were from nursing homes and 133 (42%) were from independent living. More than half (72) of the independent living patients had a primary language other than English. During the second surge (S2), 12% (13) were from nursing homes. The most common comorbidities were similar for both groups and included obesity, diabetes, and chronic lung disease. However, during the first surge, 33% (104) of the patients had dementia. The median Charlson Comorbidity Index score was worse in the first surge; the predicted 10-year survival was 21% versus 53%. The treatments given included remdesivir in 5% (16) in the first surge versus 60% (62) in the second surge. Dexamethasone was given only in the second surge in 69% (72) of the patients. Outcomes The reported outcomes are contrasted by the first versus the second surge. Admission to the intensive care unit was required in 83 (27%) of the patients during the first surge versus 15 (14%) of the patients during the second surge. Mechanical ventilation was required in 33 (11%) of the patients during the first surge versus 5 (11%) of the patients during the second surge. The overall mortality was 25% during the first surge (79) versus 9% (9) during the second surge. Conclusion Among patients with COVID-19 infection admitted to a community teaching hospital during the second Massachusetts surge, there was a significant improvement in clinical outcomes, particularly mortality, compared with patients admitted during the early pandemic. It is tempting to attribute the improved outcomes to the implementation of treatment with corticosteroids and more use of antiviral therapy. However, the patients admitted during the larger first surge were more likely to have a do not resuscitate (DNR) status on admission, be from a nursing home, have dementia, and have poorer predicted survival.
Related Concept Videos
Hospitals-I
Hospitals-II
Nurses that work in...
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
Bias in Epidemiological Studies
Comparing the Survival Analysis of Two or More Groups